Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness, today announced that safety and efficacy ...

The company’s lead program is evaluating ATSN-201 in an ongoing Phase I/II clinical trial for X-linked retinoschisis (XLRS), a genetic condition that is typically diagnosed in childhood and ...

ATSN-201 has received Orphan Drug and Rare Pediatric Disease designations from the U.S. Food and Drug Administration. About X-linked Retinoschisis (XLRS) XLRS is a monogenic X-linked disease caused by ...

3 Guangdong Provincial Clinical Research Center for Ocular Diseases, Guangzhou, People's Republic of China Aims Choroidal neovascularisation (CNV) in patients with X-linked retinoschisis (XLRS) has ...

Purpose: Carbonic anhydrase inhibitors (CAIs) reduce macular schisis in patients with X-linked retinoschisis (XLRS). The purpose of this study was to determine if CAIs reduce the incidence of ...

Introduction: X-linked retinoschisis (XLRS) is an inherited retinal disease (IRD) caused by pathogenic mutations in the retinoschisin gene, RS1. Affected individuals develop retinal layer separation, ...

Dr. Pfahler is board certified in Ophthalmology. Dr. Pfahler has has worked on more claims relating to Macular or Retinal Edema, Retinoschisis and Retinal Vascular Occlusion than other providers ...